Dexamethasone promotes hypertrophy of H9C2 cardiomyocytes through calcineurin B pathway, independent of NFAT activation
- 418 Downloads
Metabolic syndrome-induced cardiac hypertrophy is a global concern leading to an increase in the morbidity and mortality of patients, with the signalling mechanism associated with them still unclear. The present study attempts to understand the metabolic syndrome-associated cardiac hypertrophy through an in vitro model using external stimuli well known for inducing metabolic disorders, i.e. dexamethasone (DEX), a synthetic glucocorticoid. DEX (0.1 and 1 μM) promoted cardiac hypertrophy in H9C2 cells at 4 days of treatment as evidenced through increased cell size and protein content. A significant induction in foetal gene reprogramming was observed, confirming the establishment of hypertrophy. Moreover, the hypertrophic response at 4 days was perceived to be physiological at 0.1 μM and pathological at 1 μM based on α-MHC and IGF1R expression, but complete inhibition in the PKB/AKT expression confirmed it to be pathological hypertrophy at both the concentrations (0.1 and 1 μM). The present study reports for the first time the mechanistic insights into DEX-mediated hypertrophy. It is hypothesized to be orchestrated through the activation of AT1R that is involved in the alteration of the cardiac isoform of SERCA2 expression perturbing the calcium homeostasis. This leads to the activation of calcineurin B, independent of NFAT involvement, which in coordination with ROS induces the activation of JNK of the MAPK signalling.
KeywordsCalcineurin B Cardiac hypertrophy Dexamethasone H9C2 Hypertrophic signalling
This work was supported by UGC-Dr D S Kothari Postdoctoral fellowship awarded to Dr Sangeetha KN, by the University Grants Commission, Government of India [Award letter No. F. 13-673/2012(BSR)].
Compliance with ethical standards
Conflict of interest
The authors declare that there are no conflicts of interest.
- 7.Oakley RH, Cidlowski JA (2015) Glucocorticoid signalling in the heart: a cardiomyocyte perspective. J Steroid Biochem Mol Biol S0960–0760(15):00094-1Google Scholar
- 15.Sangeetha KN, Sujatha S, Muthusamy VS, Anand S, Nithya N, Velmurugan D, Arun B, Lakshmi BS (1800) (2010) 3β-taraxerol of Mangifera indica, a PI3K dependent dual activator of glucose transport and glycogen synthesis in 3T3-L1 adipocytes. BBA—Gener Subj 3:359–366Google Scholar
- 26.Reddy DS (1997) Cellular and molecular biology of cardiac hypertrophy. Curr Sci 72(1):13–30Google Scholar
- 30.Sizemore JMK, Dixon EN, Baute AJ, Waikel RL (2012) Regulation of Alpha-Myosin Heavy Chain in cardiac remodelling associated with pregnancy. FASEB J 26(922):2Google Scholar
- 31.McMullen JR, Shioi T, Huang WY, Zhang L, Tarnavski O, Bisping E, Schinke M, Kong S, Sherwood MC, Brown J, Riggi L, Kang PM, Izumo S (2004) The IGF1 receptor induces physiological heart growth via the phosphoinositide 3-kinase (p110alpha) pathway. J Biol Chem 279(6):4782–4793CrossRefPubMedGoogle Scholar
- 34.Katoh D, Hongo K, Ito K, Yoshino T, Kayama Y, Kawai M, Date T, Yoshura M (2014) Corticosteroids increase intracellular free sodium ion concentration via glucocorticoid receptor pathway in cultured neonatal rat cardiomyocytes. IJCHV 3:49–56Google Scholar